IMVT
Immunovant, Inc.
Biological Products, (No Diagnostic Substances)NasdaqLarge accelerated filer
Total Trades
139
Buys
6
Sells
132
Largest Trade
$1M+
Insiders
14
Institutional Funds
145
Inst. Value
$1M+
Activist Filings
13
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| Gloria Melanie | COO | SELL | $50K–$100K | 3K | $27.85 | Feb 27, 2026 |
| Stout Jay S | CTO | SELL | $50K–$100K | 2K | $26.03 | Jan 23, 2026 |
| Stout Jay S | CTO | SELL | $15K–$50K | 1K | $26.53 | Jan 9, 2026 |
| Van Tuyl Christopher | Chief Legal Officer | SELL | $100K–$500K | 11K | $26.91 | Dec 19, 2025 |
| Roivant Sciences Ltd. | Director | BUY | $1M+ | 16.7M | $21.00 | Dec 12, 2025 |
| Fromkin Andrew J. | Director | SELL | $500K+ | 22K | $23.25 | Dec 3, 2025 |
| Hughes Douglas J. | Director | SELL | $100K–$500K | 15K | $23.24 | Dec 3, 2025 |
| Gloria Melanie | COO | SELL | $100K–$500K | 13K | $23.62 | Nov 21, 2025 |
| Geffner Michael | Chief Medical Offi… | SELL | $15K–$50K | 3K | $19.03 | Oct 24, 2025 |
| Stout Jay S | CTO | SELL | $15K–$50K | 3K | $19.03 | Oct 24, 2025 |
| Stout Jay S | CTO | SELL | $50K–$100K | 3K | $18.15 | Jul 25, 2025 |
| Geffner Michael | Chief Medical Offi… | SELL | $15K–$50K | 2K | $18.15 | Jul 25, 2025 |
| Geffner Michael | Chief Medical Offi… | SELL | $15K–$50K | 1K | $17.24 | Jul 11, 2025 |
| Stout Jay S | CTO | SELL | $15K–$50K | 2K | $17.24 | Jul 11, 2025 |
| Stout Jay S | CTO | SELL | $15K–$50K | 2K | $14.79 | Apr 25, 2025 |
| Geffner Michael | Chief Medical Offi… | SELL | $15K–$50K | 2K | $14.79 | Apr 25, 2025 |
| Barnett Eva Renee | CFO | SELL | $15K–$50K | 3K | $14.89 | Apr 17, 2025 |
| Salzmann Peter | CEO | SELL | $100K–$500K | 8K | $14.89 | Apr 17, 2025 |
| Stout Jay S | CTO | SELL | $50K–$100K | 5K | $12.99 | Apr 11, 2025 |
| Geffner Michael | Chief Medical Offi… | SELL | $50K–$100K | 6K | $12.99 | Apr 11, 2025 |
| Barnett Eva Renee | CFO | SELL | $100K–$500K | 11K | $12.99 | Apr 11, 2025 |
| Salzmann Peter | CEO | SELL | $100K–$500K | 28K | $12.99 | Apr 11, 2025 |
| Macias William L. | Chief Medical Offi… | SELL | $15K–$50K | 2K | $20.86 | Feb 21, 2025 |
| Barnett Eva Renee | CFO | SELL | $50K–$100K | 3K | $20.86 | Feb 21, 2025 |
| Salzmann Peter | CEO | SELL | $100K–$500K | 15K | $20.86 | Feb 21, 2025 |
| Stout Jay S | CTO | SELL | $50K–$100K | 2K | $23.59 | Jan 24, 2025 |
| Geffner Michael | Chief Medical Offi… | SELL | $50K–$100K | 3K | $23.59 | Jan 24, 2025 |
| Macias William L. | Chief Medical Offi… | SELL | $50K–$100K | 2K | $23.83 | Jan 17, 2025 |
| Barnett Eva Renee | CFO | SELL | $50K–$100K | 2K | $23.83 | Jan 17, 2025 |
| Salzmann Peter | CEO | SELL | $100K–$500K | 9K | $23.83 | Jan 17, 2025 |
| Roivant Sciences Ltd. | Director | BUY | $1M+ | 16.8M | $20.00 | Jan 15, 2025 |
| Barnett Eva Renee | CFO | SELL | $50K–$100K | 4K | $24.10 | Jan 10, 2025 |
| Salzmann Peter | CEO | SELL | $100K–$500K | 5K | $24.10 | Jan 10, 2025 |
| Pande Atul | Director | SELL | $100K–$500K | 8K | $28.54 | Dec 4, 2024 |
| Hughes Douglas J. | Director | SELL | $100K–$500K | 5K | $28.54 | Dec 4, 2024 |
| Levine Mark S. | Chief Legal Officer | SELL | $50K–$100K | 4K | $25.45 | Nov 22, 2024 |
| Macias William L. | Chief Medical Offi… | SELL | $50K–$100K | 3K | $25.45 | Nov 22, 2024 |
| Barnett Eva Renee | CFO | SELL | $100K–$500K | 4K | $25.45 | Nov 22, 2024 |
| Salzmann Peter | CEO | SELL | $100K–$500K | 17K | $25.45 | Nov 22, 2024 |
| Levine Mark S. | Chief Legal Officer | SELL | $100K–$500K | 4K | $29.53 | Oct 25, 2024 |
| Geffner Michael | Chief Medical Offi… | SELL | $50K–$100K | 3K | $29.53 | Oct 25, 2024 |
| Stout Jay S | CTO | SELL | $50K–$100K | 3K | $29.53 | Oct 25, 2024 |
| Salzmann Peter | CEO | SELL | $100K–$500K | 9K | $28.79 | Oct 18, 2024 |
| Macias William L. | Chief Medical Offi… | SELL | $50K–$100K | 3K | $28.79 | Oct 18, 2024 |
| Levine Mark S. | Chief Legal Officer | SELL | $50K–$100K | 3K | $28.79 | Oct 18, 2024 |
| Barnett Eva Renee | CFO | SELL | $50K–$100K | 3K | $28.79 | Oct 18, 2024 |
| Barnett Eva Renee | CFO | SELL | $100K–$500K | 5K | $29.56 | Oct 11, 2024 |
| Salzmann Peter | CEO | SELL | $100K–$500K | 4K | $29.56 | Oct 11, 2024 |
| Levine Mark S. | Chief Legal Officer | SELL | $100K–$500K | 3K | $31.86 | Aug 23, 2024 |
| Macias William L. | Chief Medical Offi… | SELL | $50K–$100K | 3K | $31.86 | Aug 23, 2024 |
🔓Seeing ranges? Sign in for exact trade values — free forever
Institutional Ownership
13F filings as of Dec 31, 2025 · 145 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| Deep Track Capital, LP | 11.5M | $1M+ | SH |
| STATE STREET CORP | 3.8M | $1M+ | SH |
| Two Seas Capital LP | 2.9M | $1M+ | SH |
| Alpine Global Management, LLC | 2.6M | $1M+ | SH |
| ADAR1 Capital Management, LLC | 2.5M | $1M+ | SH |
| ADAR1 Capital Management, LLC | 2.5M | $1M+ | SH |
| Point72 Asset Management, L.P. | 2.0M | $1M+ | SH |
| PERCEPTIVE ADVISORS LLC | 2.0M | $1M+ | SH |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6M | $1M+ | SH |
| Logos Global Management LP | 1.4M | $1M+ | SH |
| Aberdeen Group plc | 1.2M | $1M+ | SH |
| MORGAN STANLEY | 1.2M | $1M+ | SH |
| Soleus Capital Management, L.P. | 1.1M | $1M+ | SH |
| JENNISON ASSOCIATES LLC | 700K | $1M+ | SH |
| Candriam S.C.A. | 680K | $1M+ | SH |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 643K | $1M+ | SH |
| Connor, Clark & Lunn Investment Management Ltd. | 467K | $1M+ | SH |
| Pictet Asset Management Holding SA | 381K | $1M+ | SH |
| BNP PARIBAS FINANCIAL MARKETS | 353K | $1M+ | SH |
| GOLDMAN SACHS GROUP INC | 265K | $1M+ | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
SC 13D/A · Dec 12, 2025
55.9%
113.3M shares
SC 13G/A · Nov 5, 2025
8.4%
14.7M shares
SC 13D/A · Apr 21, 2025
56.9%
96.7M shares
SC 13G · Mar 26, 2025
5.6%
9.5M shares
SC 13G/A · Mar 7, 2025
10.1%
17.1M shares
SC 13D/A · Jan 15, 2025
56.9%
96.7M shares
SC 13G/A · Nov 12, 2024
8.6%
12.5M shares
SC 13G/A · Feb 14, 2024
0.7%
1.0M shares
SC 13D/A · Oct 4, 2023
55.3%
79.8M shares
SC 13G/A · Feb 14, 2023
7.5%
9.7M shares
SC 13G/A · Dec 5, 2022
0.0%
0 shares
SC 13G/A · Dec 2, 2022
5.9%
7.6M shares
SC 13G · Feb 11, 2022
5.8%
6.8M shares